Human TNF RI/TNFRSF1A Antibody Best Seller
R&D Systems, part of Bio-Techne | Catalog # MAB625
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Western Blot, ELISA Capture (Matched Antibody Pair), Neutralization
Cited:
Western Blot, Neutralization, Flow Cytometry, Antibody Array Development, Array Development, ELISA Capture, ELISA Development, ELISA Development (Capture), Functional Assay, Neutralizing
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 16805
Product Specifications
Immunogen
E. coli-derived recombinant human TNF RI/TNFRSF1A
Extracellular domain
Extracellular domain
Specificity
Detects human TNF RI/TNFRSF1A in ELISAs and Western blots. In sandwich immunoassays, no significant cross-reactivity or interference with recombinant human (rh) TGF-alpha, hTGF-beta 1, porcine (p) TGF-beta 1, rhTGF-beta 1, pTGF-beta 1.2, pTGF-beta 2, recombinant chicken TGF-beta 3, rhTGF-beta 3, recombinant amphibian TGF-beta 5, rhTNF-beta, or rhTNF RII is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human TNF RI/TNFRSF1A Antibody
TNF RI/TNFRSF1A Inhibition of TNF‑ alpha-induced Cytotoxicity and Neutralization by Human TNF RI/TNFRSF1A Antibody.
Recombinant Human TNF RI/TNFRSF1A (Catalog # 636-R1) inhibits Recombinant Human TNF-a (Catalog # 210-TA) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human TNF-a (0.25 ng/mL) activity elicited by Recombinant Human TNF RI/TNFRSF1A (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Human TNF RI/TNFRSF1A Monoclonal Antibody (Catalog # MAB625). The ND50 is typically 1-6 µg/mL in the presence of the metabolic inhibitor actinomycin D (1 µg/mL).
Detection of TNF RI/TNFRSF1A by Western Blot
Inhibition assays with antibody against tumor necrosis factor-receptor 1 (TNFR1AB). (A) Analysis of nuclear factor-kappa-B (NF-kappa B) phosphorylation upon blockade of TNFR1. Dental pulp stems (DPCs) were incubated with different concentrations (0, 4, 6, and 10 μg/mL) of TNFR1AB for 1 hour prior to treatment with TNF-alpha (10 ng/mL). Phosphorylation of NF-kappa B (p65, p105) was examined by Western blot at 5 minutes after stimulation. TNFR1AB inhibited TNF-alpha -induced phosphorylation of p105 and p65 in a dose-dependent manner, and a maximum effect was observed with a concentration of 10 μg/mL. (B) Flow cytometric analysis of expression of stage-specific embryonic antigen 4 (SSEA-4). TNFR1AB only partially inhibited TNF-alpha -induced increase in the number of SSEA-4+ cells. (C) Analysis of mRNA levels of OCT-4 and NANOG upon inhibition of TNFR1. Although TNF-alpha treatment increased the gene expression of OCT-4 and NANOG, TNFR1AB nullified the TNF-alpha -induced increase OCT-4 mRNA levels only. **P <0.01, one-way analysis of variance (ANOVA), Tukey test. Data are representative of at least three different experiments. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24580841), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human TNF RI/TNFRSF1A Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: Recombinant Human TNF RI/TNFRSF1A (Catalog # 636-R1)
under non-reducing conditions only
Sample: Recombinant Human TNF RI/TNFRSF1A (Catalog # 636-R1)
under non-reducing conditions only
Neutralization
Measured by its ability to neutralize TNF RI/TNFRSF1A-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 1-6 µg/mL in the presence of 0.3 μg/mL Recombinant Human TNF RI/TNFRSF1A, 0.25 ng/mL Recombinant Human TNF‑ alpha, and 1 µg/mL actinomycin D.
Human TNF RI/TNFRSF1A Sandwich Immunoassay
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 2 reviews rated 5 using MAB625 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TNF RI/TNFRSF1A
TNF RI occurs both in membrane bound and soluble forms and functions as a receptor for TNF-alpha and TNF-beta. In the superfamily nomenclature, it is designated TNFRSF1A.
Long Name
Tumor Necrosis Factor Receptor I
Alternate Names
CD120a, TNFRI, TNFRSF1A
Gene Symbol
TNFRSF1A
Additional TNF RI/TNFRSF1A Products
Product Documents for Human TNF RI/TNFRSF1A Antibody
Product Specific Notices for Human TNF RI/TNFRSF1A Antibody
For research use only
Loading...
Loading...
Loading...
Loading...